Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
430 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00480025 | GSK1572932A Antigen-Specific Cancer Immunotherapeutic as Adjuvant Therapy in Patients With Non-Small Cell Lung Cancer | terminated | Phase 3 | 2,278 | GlaxoSmithKlineINDUSTRY | 34 | Dec 22, 2020 | clinicaltrials |
| NCT00471497 | A Study of Imatinib Versus Nilotinib in Adult Patients With Newly Diagnosed Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia in Chronic Phase (CML-CP)(ENESTnd) | completed | Phase 3 | 846 | Novartis PharmaceuticalsINDUSTRY | 35 |
| Nov 18, 2020 |
| clinicaltrials |
| NCT00082433 | Epothilone (Ixabepilone) Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 1,221 | R-PharmINDUSTRY | 29 | Nov 2, 2020 | clinicaltrials |
| NCT04448522 | Reduced vs Conventional Dosage Intensity-modulated Radiotherapy for Chemotherapy-sensitive Stage II-III Nasopharyngeal Carcinoma | recruiting | Phase 3 | 508 | Sun Yat-sen UniversityOTHER | 2 | Sep 28, 2020 | clinicaltrials |
| NCT01610284 | Phase III Study of BKM120/Placebo With Fulvestrant in Postmenopausal Patients With Hormone Receptor Positive HER2-negative Locally Advanced or Metastatic Breast Cancer Refractory to Aromatase Inhibitor(BELLE-2) | completed | Phase 3 | 1,147 | Novartis PharmaceuticalsINDUSTRY | 29 | Aug 25, 2020 | clinicaltrials |
| NCT01774344 | Study of Regorafenib After Sorafenib in Patients With Hepatocellular Carcinoma(RESORCE) | completed | Phase 3 | 573 | BayerINDUSTRY | 21 | Aug 20, 2020 | clinicaltrials |
| NCT03745222 | A Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer(RATIONALE001) | terminated | Phase 3 | 1 | CelgeneINDUSTRY | 23 | Jul 15, 2020 | clinicaltrials |
| NCT02718417 | Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100) | terminated | Phase 3 | 998 | PfizerINDUSTRY | 25 | Jul 14, 2020 | clinicaltrials |
| NCT00337103 | E7389 Versus Capecitabine in Patients With Locally Advanced or Metastatic Breast Cancer Previously Treated With Anthracyclines and Taxanes | completed | Phase 3 | 1,276 | Eisai Inc.INDUSTRY | 23 | Jun 18, 2020 | clinicaltrials |
| NCT01285609 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Versus Placebo in Addition to Paclitaxel and Carboplatin | completed | Phase 3 | 1,289 | Bristol-Myers SquibbINDUSTRY | 36 | Jun 18, 2020 | clinicaltrials |
| NCT00418457 | Regional Anesthesia and Breast Cancer Recurrence | completed | Phase 3 | 2,108 | The Cleveland ClinicOTHER | 6 | Jun 16, 2020 | clinicaltrials |
| NCT02043288 | Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Pancreatic Cancer | completed | Phase 3 | 310 | Orient Europharma Co., Ltd.INDUSTRY | 7 | Apr 15, 2020 | clinicaltrials |
| NCT00026338 | Gemcitabine With/Out Erlotinib in Unresectable Locally Advanced/Metastatic Pancreatic Cancer | completed | Phase 3 | 569 | NCIC Clinical Trials GroupNETWORK | 19 | Apr 2, 2020 | clinicaltrials |
| NCT01023308 | Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma(PANORAMA-1) | completed | Phase 3 | 767 | Novartis PharmaceuticalsINDUSTRY | 34 | Mar 17, 2020 | clinicaltrials |
| NCT01212991 | A Safety and Efficacy Study of Oral MDV3100 in Chemotherapy-Naive Patients With Progressive Metastatic Prostate Cancer(PREVAIL) | completed | Phase 3 | 1,717 | PfizerINDUSTRY | 22 | Mar 17, 2020 | clinicaltrials |
| NCT00069121 | A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer | completed | Phase 3 | 1,886 | Hoffmann-La RocheINDUSTRY | 29 | Mar 6, 2020 | clinicaltrials |
| NCT00294047 | Study to Evaluate the Efficacy of the Human Papillomavirus Vaccine in Healthy Adult Women of 26 Years of Age and Older | completed | Phase 3 | 5,752 | GlaxoSmithKlineINDUSTRY | 12 | Jan 2, 2020 | clinicaltrials |
| NCT00567190 | A Study to Evaluate Pertuzumab + Trastuzumab + Docetaxel vs. Placebo + Trastuzumab + Docetaxel in Previously Untreated HER2-Positive Metastatic Breast Cancer(CLEOPATRA) | completed | Phase 3 | 808 | Genentech, Inc.INDUSTRY | 26 | Dec 13, 2019 | clinicaltrials |
| NCT01249365 | The Safety Evaluation of the GSK-580299 Vaccine in Women From the Control Group in the Primary NCT00294047 Study | completed | Phase 3 | 199 | GlaxoSmithKlineINDUSTRY | 4 | Nov 13, 2019 | clinicaltrials |
| NCT01721954 | FOLFOX6m Plus SIR-Spheres Microspheres vs FOLFOX6m Alone in Patients With Liver Mets From Primary Colorectal Cancer(FOXFIREGlobal) | completed | Phase 3 | 209 | Sirtex MedicalINDUSTRY | 13 | Nov 5, 2019 | clinicaltrials |
| NCT01190176 | Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects | completed | Phase 3 | 34 | GlaxoSmithKlineINDUSTRY | 7 | Oct 30, 2019 | clinicaltrials |
| NCT01170663 | A Study of Paclitaxel With or Without Ramucirumab (IMC-1211B) in Metastatic Gastric Adenocarcinoma(RAINBOW) | completed | Phase 3 | 665 | Eli Lilly and CompanyINDUSTRY | 26 | Sep 18, 2019 | clinicaltrials |
| NCT02279732 | Phase 3 Trial in Squamous Non Small Cell Lung Cancer Subjects Comparing Ipilimumab Plus Paclitaxel and Carboplatin Versus Placebo Plus Paclitaxel and Carboplatin | completed | Phase 3 | 342 | Bristol-Myers SquibbINDUSTRY | 6 | Aug 28, 2019 | clinicaltrials |
| NCT01818752 | Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma(CLARION) | completed | Phase 3 | 955 | AmgenINDUSTRY | 30 | Aug 26, 2019 | clinicaltrials |
| NCT01953913 | Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation | completed | Phase 3 | 542 | Boehringer IngelheimINDUSTRY | 5 | Aug 12, 2019 | clinicaltrials |
| NCT01125566 | LUX-Breast 1: BIBW 2992 (Afatinib) in HER2-positive Metastatic Breast Cancer Patients After One Prior Herceptin Treatment | completed | Phase 3 | 508 | Boehringer IngelheimINDUSTRY | 38 | Jul 18, 2019 | clinicaltrials |
| NCT00901901 | Nexavar-Tarceva Combination Therapy for First Line Treatment of Patients Diagnosed With Hepatocellular Carcinoma(SEARCH) | completed | Phase 3 | 732 | BayerINDUSTRY | 26 | May 30, 2019 | clinicaltrials |
| NCT01953003 | Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer | completed | Phase 3 | 112 | Pierre Fabre MedicamentINDUSTRY | 3 | May 2, 2019 | clinicaltrials |
| NCT02131155 | LUX-Head & Neck 4: Afatinib (BIBW 2992) Versus Placebo for the Treatment of Head and Neck Squamous Cell Cancer After Treatment With Chemo-radiotherapy | terminated | Phase 3 | 36 | Boehringer IngelheimINDUSTRY | 4 | Mar 1, 2019 | clinicaltrials |
| NCT01523587 | LUX-Lung 8: A Phase III Trial of Afatinib (BIBW 2992) Versus Erlotinib for the Treatment of Squamous Cell Lung Cancer After at Least One Prior Platinum Based Chemotherapy | completed | Phase 3 | 795 | Boehringer IngelheimINDUSTRY | 23 | Feb 15, 2019 | clinicaltrials |
| NCT02605044 | Masitinib in Combination With FOLFIRI for Second-line Treatment of Patients With Metastatic Colorectal Cancer | terminated | Phase 3 | 123 | AB ScienceINDUSTRY | 3 | Feb 11, 2019 | clinicaltrials |
| NCT00678392 | Axitinib (AG 013736) As Second Line Therapy For Metastatic Renal Cell Cancer | completed | Phase 3 | 723 | PfizerINDUSTRY | 22 | Jan 9, 2019 | clinicaltrials |
| NCT01564784 | A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia | completed | Phase 3 | 326 | PfizerINDUSTRY | 20 | Jan 9, 2019 | clinicaltrials |
| NCT00574873 | Compare Bosutinib To Imatinib In Subjects With Newly Diagnosed Chronic Phase Philadelphia Chromosome Positive CML | completed | Phase 3 | 502 | PfizerINDUSTRY | 29 | Jan 8, 2019 | clinicaltrials |
| NCT01200758 | A Study of Rituximab (MabThera) Subcutaneous (SC) Versus Rituximab (MabThera) Intravenous in Participannts With Follicular Non-Hodgkin's Lymphoma | completed | Phase 3 | 410 | Hoffmann-La RocheINDUSTRY | 30 | Nov 27, 2018 | clinicaltrials |
| NCT01732913 | Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas(Yosemite) | terminated | Phase 3 | 295 | Gilead SciencesINDUSTRY | 19 | Nov 16, 2018 | clinicaltrials |
| NCT01313689 | Ofatumumab vs Physician's Choice in Subjects With Bulky Fludarabine-Refractory Chronic Lymphocytic Leukemia | completed | Phase 3 | 122 | Novartis PharmaceuticalsINDUSTRY | 17 | Nov 8, 2018 | clinicaltrials |
| NCT01810770 | Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone Metastasis | completed | Phase 3 | 243 | BayerINDUSTRY | 4 | Sep 19, 2018 | clinicaltrials |
| NCT00692770 | Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)(STORM) | completed | Phase 3 | 1,114 | BayerINDUSTRY | 28 | Aug 8, 2018 | clinicaltrials |
| NCT00722137 | Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma | completed | Phase 3 | 487 | Millennium Pharmaceuticals, Inc.INDUSTRY | 29 | Jul 12, 2018 | clinicaltrials |
| NCT01767467 | Study to Assess the Safety and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine in Adults Aged 18 Years and Older With Blood Cancers | completed | Phase 3 | 568 | GlaxoSmithKlineINDUSTRY | 21 | Jun 6, 2018 | clinicaltrials |
| NCT03518957 | 12-week Exercise Intervention Program Versus Observation in Early Stage Breast Cancer Patients on the Impact on Mental Health, Quality of Life and Immune Markers | unknown | Phase 3 | 304 | National University Hospital, SingaporeOTHER | 1 | May 14, 2018 | clinicaltrials |
| NCT01135056 | Study to Compare Selective Internal Radiation Therapy (SIRT) Versus Sorafenib in Locally Advanced Hepatocellular Carcinoma (HCC)(SIRveNIB) | unknown | Phase 3 | 360 | Singapore General HospitalOTHER | 12 | Apr 24, 2018 | clinicaltrials |
| NCT00758186 | Randomized Trial of Colonic Stents as a Bridge to Surgery | completed | Phase 3 | 40 | Singapore General HospitalOTHER | 1 | Apr 18, 2018 | clinicaltrials |
| NCT00036647 | OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer | completed | Phase 3 | 731 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT00040183 | OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer. | completed | Phase 3 | 569 | OSI PharmaceuticalsINDUSTRY | 17 | Jan 10, 2018 | clinicaltrials |
| NCT01281254 | AMG 386 (Trebananib) in Ovarian Cancer (TRINOVA-2) | terminated | Phase 3 | 223 | AmgenINDUSTRY | 18 | Dec 2, 2017 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials